Institutional Investors Are Crazy For CareDx (NASDAQ:CDNA)

Sentiment for CareDx (NASDAQ:CDNA)

CareDx (NASDAQ:CDNA) institutional sentiment increased to 1.63 in Q2 2019. Its up 0.05, from 1.58 in 2019Q1. The ratio has improved, as 96 investment professionals started new or increased equity positions, while 59 cut down and sold equity positions in CareDx. The investment professionals in our partner’s database now own: 38.15 million shares, up from 35.39 million shares in 2019Q1. Also, the number of investment professionals holding CareDx in their top 10 equity positions decreased from 5 to 4 for a decrease of 1. Sold All: 22 Reduced: 37 Increased: 64 New Position: 32.

CareDx, Inc., together with its subsidiaries, focuses on the discovery, development, and commercialization of diagnostic surveillance solutions for transplant patients in North America, Europe, the Middle East, Africa, and Latin America. The company has market cap of $1.19 billion. The firm operates through two divisions, CareDx and Olerup. It currently has negative earnings. The Company’s commercialized testing solution includes the AlloMap heart transplant molecular test , a gene expression test that helps clinicians monitor and identify heart transplant recipients with stable graft function who have a low probability of moderate/severe acute cellular rejection.

The stock increased 3.34% or $0.91 during the last trading session, reaching $28.15. About 768,378 shares traded. CareDx, Inc (NASDAQ:CDNA) has risen 170.83% since October 12, 2018 and is uptrending. It has outperformed by 170.83% the S&P500.

Analysts await CareDx, Inc (NASDAQ:CDNA) to report earnings on November, 14. They expect $-0.16 earnings per share, up 70.37 % or $0.38 from last year’s $-0.54 per share. After $-0.19 actual earnings per share reported by CareDx, Inc for the previous quarter, Wall Street now forecasts -15.79 % EPS growth.

Gagnon Securities Llc holds 7.87% of its portfolio in CareDx, Inc for 1.01 million shares. Gagnon Advisors Llc owns 293,785 shares or 6.04% of their US portfolio. Moreover, Next Century Growth Investors Llc has 3.28% invested in the company for 731,460 shares. The Minnesota-based Perkins Capital Management Inc has invested 3.19% in the stock. Rk Capital Management Llc, a Colorado-based fund reported 174,000 shares.

CareDx, Inc (NASDAQ:CDNA) Ratings Coverage

Ratings analysis reveals 100% of CareDx’s analysts are positive. Out of 2 Wall Street analysts rating CareDx, 2 give it “Buy”, 0 “Sell” rating, while 0 recommend “Hold”. The lowest target is $3000 while the high is $4800. The stock’s average target of $42 is 49.20% above today’s ($28.15) share price. CDNA was included in 4 notes of analysts from May 9, 2019. Raymond James maintained it with “Strong Buy” rating and $4800 target in Friday, August 2 report.

More notable recent CareDx, Inc (NASDAQ:CDNA) news were published by: Globenewswire.com which released: “CareDx Reports Second Quarter 2019 Results Nasdaq:CDNA – GlobeNewswire” on August 01, 2019, also Globenewswire.com with their article: “AlloSure now available for Lung Transplant Patients – GlobeNewswire” published on February 21, 2019, Finance.Yahoo.com published: “We’re Excited To See How CareDx (NASDAQ:CDNA) Uses Its Cash Hoard To Grow – Yahoo Finance” on October 12, 2019. More interesting news about CareDx, Inc (NASDAQ:CDNA) were released by: Globenewswire.com and their article: “CareDx Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) – GlobeNewswire” published on September 11, 2019 as well as Globenewswire.com‘s news article titled: “AlloSure Heart Clinical Validation Published in Leading Transplant Journal – GlobeNewswire” with publication date: March 11, 2019.

CareDx, Inc (NASDAQ:CDNA) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.